CEMM FORSCHUNGSZENTRUM FUR MOLEKULARE MEDIZIN GMBH has a total of 28 patent applications. It increased the IP activity by 0.0%. Its first patent ever was published in 2011. It filed its patents most often in Australia, Israel and Canada. Its main competitors in its focus markets pharmaceuticals, measurement and biotechnology are CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH, CEMM FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GMBH and CHU SAINTE JUSTINE.
# | Country | Total Patents | |
---|---|---|---|
#1 | Australia | 6 | |
#2 | Israel | 6 | |
#3 | Canada | 5 | |
#4 | Republic of Korea | 5 | |
#5 | China | 4 | |
#6 | United States | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Measurement | |
#3 | Biotechnology | |
#4 | Organic fine chemistry | |
#5 | Environmental technology | |
#6 | Chemical engineering |
# | Name | Total Patents |
---|---|---|
#1 | Kubicek Stefan | 7 |
#2 | Kralovics Robert | 5 |
#3 | Gisslinger Heinz | 5 |
#4 | Sdelci Sara | 5 |
#5 | Klampfl Thorsten | 5 |
#6 | Superti-Furga Giulio | 4 |
#7 | Krall Nikolaus | 4 |
#8 | Snijder Berend | 3 |
#9 | Ioannou Loizou Joanna | 2 |
#10 | Vladimer Gregory Ian | 2 |
Publication | Filing date | Title |
---|---|---|
AU2018359500A1 | Methods for determining selectivity of test compounds | |
CN109153647A | TAF1 inhibitor for treating cancer | |
AU2013307383A1 | Aminoheteroaryl compounds as MTH1 inhibitors |